References
Depression, Anxiety, HAD
Analysis of the clinical and pharmacology data at the baseline and after the 3-month opioid titration procedure (final visit) by comparing the pharmacogenetic-guided therapy (cases) to usual prescribing (controls). * Denotes Study flow chart from the baseline to the final visit after 3 months of opioid titration.Description of the relation between the different opioids and coadjutant analgesic drugs with the Baseline demographic and genetic characteristics of chronic non-cancer pain (CNCP) patients in both clinical trial arms: pharmacogenetic (PGx) guided opioid therapy (cases) vs. usual routine care (controls).* Denotes Clinical and pharmacological data of the chronic non-cancer pain patients in both clinical trial arms: pharmacogenetic (PGx)-guided opioid therapy (cases) vs. usual routine care (controls) before and after opioid treatment.HAD: Hospital Anxiety and Depression Scale; SF12: Short Format Health Survey 12; MEDD: morphine equivalent daily dose; NSAIDs: non-steroidal anti-inflammatory drugs. * Denotes Safety data of the chronic non-cancer pain patients in both clinical trial arms: pharmacogenetic (PGx)-guided opioid therapy (cases) vs. usual routine care (controls) before and after opioid treatment.* Denotes Recommendations for opioid prescribing based on the 